In a groundbreaking advancement, researchers from Mass General Brigham have developed an innovative gene therapy that targets the lungs and airways through a simple nasal spray. This novel method leverages a newly engineered version of adeno-associated viruses (AAV), known as AAV.CPP.16, to deliver therapeutic molecules more effectively to the desired locations within the body.
Gene therapy’s success largely hinges on the efficient delivery of therapeutic molecules to specific areas, a task traditionally assigned to AAVs. The newly developed AAV.CPP.16 signifies a significant improvement over its predecessors, AAV6 and AAV9, by demonstrating superior targeting capabilities for lung and airway tissues in preclinical models. This advancement holds promise for the treatment of respiratory diseases and viral infections.
Initial tests indicated that AAV.CPP.16, originally designed for targeting the central nervous system, also efficiently entered lung cells. Encouraged by these findings, researchers redirected their efforts to explore its potential for respiratory gene therapy. Using cell culture, mouse, and non-human primate models, AAV.CPP.16 achieved notable improvements. In particular, experiments showed its effectiveness in delivering gene therapy to prevent lung scarring in pulmonary fibrosis and in halting the replication of the SARS-CoV-2 virus in COVID-19 models.
The promising results fuel optimism for the translational potential of this new gene delivery mechanism. “Although further research is needed, our findings suggest that intranasal AAV.CPP.16 holds great promise as a delivery tool for targeting lung and airway diseases,” notes senior author Fengfeng Bei, PhD, from Brigham and Women’s Hospital.
In conclusion, the development of AAV.CPP.16 as a nasal spray delivers a significant leap forward for gene therapy in treating lung and airway diseases. Its effectiveness in preclinical models opens the door for further research and potential clinical applications, marking a vital step toward more accessible and effective treatments for respiratory and viral conditions. As research progresses, this technology may become an invaluable tool in fighting respiratory diseases, giving hope to millions affected worldwide.